Alkermes Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alkermes Plc (ALKS)
Track today's live Alkermes Plc (ALKS) share price, performance and key data on this page with our current NASDAQ:ALKS stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Alkermes Plc share price on the NASDAQ exchange. Use the dropdown to switch exchange for the ALKS share price, head to our technical summary section, which provides analysis on Alkermes Plc share price buy/sell indicators using real-time data (or discuss the Alkermes Plc (ALKS) stock price today with other investors in the Alkermes Plc NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ALKS share price (ISIN: IE00B56GVS15) to enhance your trading decisions with our free investment tools and resources.
What Is the Alkermes Plc Share Price Today?
The Alkermes Plc share price today is 46.88.
What Is the Stock Symbol for Alkermes Plc
The stock symbol (or 'ticker') for Alkermes Plc is "ALKS."
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the NASDAQ stock exchange.
Is Alkermes Plc a Good Stock to Buy?
Determining whether Alkermes Plc (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ALKS share price (ISIN: IE00B56GVS15) to enhance your trading decisions with our free investment tools and resources.
What Is the Alkermes Plc Share Price Today?
The Alkermes Plc share price today is 46.88.
What Is the Stock Symbol for Alkermes Plc
The stock symbol (or 'ticker') for Alkermes Plc is "ALKS."
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the NASDAQ stock exchange.
Is Alkermes Plc a Good Stock to Buy?
Determining whether Alkermes Plc (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.71
48.29
52 wk Range
25.17
55.67
ALKS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.7148.29
52 wk Range
25.1755.67
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALKS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
56.00
Upside
+19.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Form 8K Alkermes plc. For: 12 August- Investing.com
Form 4 Alkermes plc. For: 3 August- Investing.com
- Alkermes Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
14 Buy
3 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 56.00
(+19.45% Upside)
Alkermes Plc Earnings Call Summary for Q2/2026
- Alkermes beat Q2 estimates with revenue of $496M (+8% vs. forecast) and adjusted EPS of $0.00, but shares fell 4.46% on rising costs.
- Proprietary product sales surged 34% YoY to $411.7M, driven by LUMRYZ ($96.6M) following Avadel acquisition integration.
- Company widened full-year GAAP net loss guidance to $95M-$115M due to contingent consideration charges from Avadel deal.
- Q3 revenue guided at $450M-$470M; key catalysts include ALKS 7290 ADHD data by Q3-end and LUMRYZ sNDA filing for idiopathic hypersomnia.
- Management emphasized orexin pipeline as long-term growth driver, positioning alixorexton as leading orexin 2 receptor agonist across narcolepsy types.
Last Updated: 28/07/2026, 14:28
Read Full TranscriptEarnings
Latest Release
28/07/2026
EPS / Forecast
-- / -0.02
Revenue / Forecast
496.01M / 458.98M
Compare ALKS to Peers and Sector
Metrics to compare | ALKS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALKSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 118.9x | 19.3x | −0.4x | |
PEG Ratio | −1.49 | −0.03 | 0.00 | |
Price/Book | 4.3x | 2.8x | 2.6x | |
Price / LTM Sales | 4.7x | 2.1x | 3.1x | |
Upside (Analyst Target) | 21.5% | 21.2% | 49.6% | |
Fair Value Upside | Unlock | 33.6% | 7.1% | Unlock |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alkermes Plc (NASDAQ: ALKS) Share Price Today?
The Alkermes Plc stock price today is 46.88 USD.
What Stock Exchange Does Alkermes Plc (ALKS) Trade On?
Alkermes Plc is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Alkermes Plc?
The stock symbol (also called a 'ticker') for Alkermes Plc is "ALKS."
What Is the Current Alkermes Plc Market Capitalisation?
As of today, Alkermes Plc (NASDAQ: ALKS) market cap is 7.86B USD.
What Is Alkermes Plc's (ALKS) Earnings Per Share (TTM)?
The Alkermes Plc EPS is currently 0.39 (Trailing Twelve Months).
When Is the Next Alkermes Plc Earnings Date?
Alkermes Plc's next earnings report will be released on 28/10/2026.
Is ALKS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Alkermes Plc moving averages and other technical indicators, the daily buy/sell signal for ALKS stock is Strong Sell.
How Many Times Has Alkermes Plc Stock Split?
Alkermes Plc has split 1 times. (See the ALKS stock split history page for full effective split date and price information.)
How Many Employees Does Alkermes Plc Have?
Alkermes Plc has 2050 employees, based on their latest Companies House report.
What is the current trading status of Alkermes Plc (NASDAQ: ALKS)?
As of 04/09/2026, Alkermes Plc (ALKS) is trading at a share price of 46.88 USD, with a previous close of 47.72 USD. The stock has fluctuated within a day range of 46.71 USD to 48.29 USD, while its 52-week range spans from 25.17 USD to 55.67 USD.
What Is Alkermes Plc (ALKS) Price Target According to Analysts?
The average 12-month price target for Alkermes Plc is 56.00 USD, with a high estimate of 72 USD and a low estimate of 38 USD. 14 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +19.45% Upside potential.
What Is the ALKS Premarket Price?
ALKS's last pre-market stock price is 48.36 USD. The pre-market share volume is 386.00, and the stock has decreased by 0.64, or 1.34%.
What Is the ALKS After Hours Price?
ALKS's last after hours stock price is 46.68 USD, the stock has decreased by -0.20, or -0.43%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.